Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial
In patients with relapsed or refractory (r/r) acute myeloid leukemia (AML), long-term disease control can only be achieved by allogeneic hematopoietic stem cell transplantation (HSCT). We studied the safety and efficacy of clofarabine-based salvage therapy. The study was designed as phase II, multic...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2016
|
| In: |
Leukemia
Year: 2015, Jahrgang: 30, Heft: 2, Pages: 261-267 |
| ISSN: | 1476-5551 |
| DOI: | 10.1038/leu.2015.226 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1038/leu.2015.226 Verlag, Volltext: https://www-nature-com.ezproxy.medma.uni-heidelberg.de/articles/leu2015226 
|
| Verfasserangaben: | J.M. Middeke, R. Herbst, S. Parmentier, G. Bug, M. Hänel, G. Stuhler, K. Schäfer-Eckart, W. Rösler, S. Klein, W. Bethge, U. Bitz, B. Büttner, H. Knoth, N. Alakel, M. Schaich, A. Morgner, M. Kramer, K. Sockel, M. von Bonin, F. Stölzel, U. Platzbecker, C. Röllig, C. Thiede, G. Ehninger, M. Bornhäuser and J. Schetelig for the Study Alliance Leukemia (SAL) |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1587228475 | ||
| 003 | DE-627 | ||
| 005 | 20230427034228.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 190204r20162015xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/leu.2015.226 |2 doi | |
| 035 | |a (DE-627)1587228475 | ||
| 035 | |a (DE-576)517228475 | ||
| 035 | |a (DE-599)BSZ517228475 | ||
| 035 | |a (OCoLC)1341035056 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Middeke, Jan Moritz |d 1980- |e VerfasserIn |0 (DE-588)1044764708 |0 (DE-627)77277319X |0 (DE-576)398114358 |4 aut | |
| 245 | 1 | 0 | |a Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML |b results of the BRIDGE trial |c J.M. Middeke, R. Herbst, S. Parmentier, G. Bug, M. Hänel, G. Stuhler, K. Schäfer-Eckart, W. Rösler, S. Klein, W. Bethge, U. Bitz, B. Büttner, H. Knoth, N. Alakel, M. Schaich, A. Morgner, M. Kramer, K. Sockel, M. von Bonin, F. Stölzel, U. Platzbecker, C. Röllig, C. Thiede, G. Ehninger, M. Bornhäuser and J. Schetelig for the Study Alliance Leukemia (SAL) |
| 264 | 1 | |c 2016 | |
| 300 | |a 7 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 04.02.2019 | ||
| 500 | |a Advance online publication, 11 September 2015 | ||
| 520 | |a In patients with relapsed or refractory (r/r) acute myeloid leukemia (AML), long-term disease control can only be achieved by allogeneic hematopoietic stem cell transplantation (HSCT). We studied the safety and efficacy of clofarabine-based salvage therapy. The study was designed as phase II, multicenter, intent-to-transplant (ITT) study. A total of 84 patients with r/r AML were enrolled. All patients received at least one cycle of CLARA (clofarabine 30 mg/m2 and cytarabine 1 g/m2, days 1-5). Chemo-responsive patients with a donor received HSCT in aplasia after first CLARA. Generally, HSCT was performed as soon as possible. The conditioning regimen consisted of clofarabine (4 × 30 mg/m2) and melphalan (140 mg/m2). The median patient age was 61 years (range 40-75). On day 15 after start of CLARA, 26% of patients were in a morphologically leukemia-free state and 79% exposed a reduction in bone marrow blasts. Overall, 67% of the patients received HSCT within the trial. The primary end point, defined as complete remission after HSCT, was achieved by 60% of the patients. According to the ITT, overall survival at 2 years was 43% (95% confidence interval (CI), 32-54%). The 2-year disease-free survival for transplanted patients was 52% (95% CI, 40-69%). Clofarabine-based salvage therapy combined with allogeneic HSCT in aplasia shows promising results in patients with r/r AML. | ||
| 534 | |c 2015 | ||
| 700 | 1 | |a Klein, Stefan |e VerfasserIn |0 (DE-588)1042491836 |0 (DE-627)769066372 |0 (DE-576)393988791 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Leukemia |d London : Springer Nature, 1997 |g 30(2016), 2, Seite 261-267 |h Online-Ressource |w (DE-627)32046699X |w (DE-600)2008023-2 |w (DE-576)094139733 |x 1476-5551 |7 nnas |a Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML results of the BRIDGE trial |
| 773 | 1 | 8 | |g volume:30 |g year:2016 |g number:2 |g pages:261-267 |g extent:7 |a Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML results of the BRIDGE trial |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/leu.2015.226 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://www-nature-com.ezproxy.medma.uni-heidelberg.de/articles/leu2015226 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20190204 | ||
| 993 | |a Article | ||
| 994 | |a 2016 | ||
| 998 | |g 1042491836 |a Klein, Stefan |m 1042491836:Klein, Stefan |d 60000 |d 61200 |e 60000PK1042491836 |e 61200PK1042491836 |k 0/60000/ |k 1/60000/61200/ |p 9 | ||
| 999 | |a KXP-PPN1587228475 |e 3053794136 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["J.M. Middeke, R. Herbst, S. Parmentier, G. Bug, M. Hänel, G. Stuhler, K. Schäfer-Eckart, W. Rösler, S. Klein, W. Bethge, U. Bitz, B. Büttner, H. Knoth, N. Alakel, M. Schaich, A. Morgner, M. Kramer, K. Sockel, M. von Bonin, F. Stölzel, U. Platzbecker, C. Röllig, C. Thiede, G. Ehninger, M. Bornhäuser and J. Schetelig for the Study Alliance Leukemia (SAL)"]},"id":{"eki":["1587228475"],"doi":["10.1038/leu.2015.226"]},"origin":[{"dateIssuedKey":"2016","dateIssuedDisp":"2016"}],"relHost":[{"title":[{"title_sort":"Leukemia","subtitle":"normal and malignant hemopoiesis ; a peer-reviewed journal","title":"Leukemia"}],"recId":"32046699X","language":["eng"],"disp":"Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML results of the BRIDGE trialLeukemia","note":["Gesehen am 15.03.04"],"type":{"bibl":"periodical","media":"Online-Ressource"},"part":{"volume":"30","text":"30(2016), 2, Seite 261-267","extent":"7","year":"2016","pages":"261-267","issue":"2"},"pubHistory":["Nachgewiesen 11.1997 -"],"id":{"issn":["1476-5551"],"eki":["32046699X"],"zdb":["2008023-2"]},"origin":[{"publisherPlace":"London ; Basingstoke [u.a.] ; Basingstoke","dateIssuedKey":"1997","publisher":"Springer Nature ; Stockton Press ; Nature Publ. Group","dateIssuedDisp":"1997-"}],"physDesc":[{"extent":"Online-Ressource"}]}],"physDesc":[{"extent":"7 S."}],"person":[{"roleDisplay":"VerfasserIn","display":"Middeke, Jan Moritz","role":"aut","family":"Middeke","given":"Jan Moritz"},{"roleDisplay":"VerfasserIn","display":"Klein, Stefan","role":"aut","family":"Klein","given":"Stefan"}],"title":[{"subtitle":"results of the BRIDGE trial","title":"Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML","title_sort":"Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML"}],"recId":"1587228475","language":["eng"],"note":["Gesehen am 04.02.2019","Advance online publication, 11 September 2015"],"type":{"media":"Online-Ressource","bibl":"article-journal"}} | ||
| SRT | |a MIDDEKEJANCLOFARABIN2016 | ||